Results 31 to 40 of about 642,659 (199)

Synthesis of a Complex and Highly Potent PCSK9 Inhibitor

, 2023
The solution-based gram-scale synthesis of complex and highly potent proprotein convertase subtilisin-like/kexin type 9 (PCSK9) inhibitor 1 is presented.
Jeffrey T. Kuethe (1437001), Jimmy DaSilva (1458121), Mirlinda Biba (2451073), Joshua Lee (437053), Erik L. Regalado (534558), Guilherme Dal Poggetto, Jimmy DaSilva, Hongming Li (296020), Fuh-Rong Tsay, David Thaisrivongs (16468359), Ryan Cohen (1748239), Guilherme Dal Poggetto (16468362), Ji Qi, David Thaisrivongs, Ryan Cohen, Nobuyoshi Yasuda, Scott R. Pollack (2467918), Erik L. Regalado, Joseph Leone (4987382), Mirlinda Biba, Nobuyoshi Yasuda (1458118), Fuh-Rong Tsay (1479709), Joshua Lee, Jeffrey T. Kuethe, Hongming Li, Ji Qi (49471), Joseph Leone, Scott R. Pollack   +27 more
core   +1 more source

Nicotine regulates PCSK9 expression in HepG2 cells through Raf/MEK/ERK signaling pathway

陆军军医大学学报, 2023
Objective To investigate the effect of nicotine (NIC) on the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) and its molecular mechanism.
ZHOU Lin, XIANG Rui, MAO Min, FENG Rui, HU Yuhao   +4 more
doaj   +1 more source

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence, Robinson, Jennifer G., Kastelein, John J.P., Roth, Eli M., Colhoun, Helen M., Pordy, Robert, Taskinen, Marja-Riitta, Ginsberg, Henry N., Kastelein, John J. P., Baccara-Dinet, Marie T.   +9 more
core   +1 more source

Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations. [PDF]

, 2011
Elevated plasma levels of lipoprotein-associated phospholipase A(2) (Lp-PLA2) activity have been shown to be associated with increased risk of coronary heart disease and an inhibitor of this enzyme is under development for the treatment of that condition.
Bacanu, S.A., E S Manas, Kong, X., Aponte, J., Manas, ES, S-A Bacanu, Cardon, L., Song, K, Nelson, MR, K Song, J Aponte, X Kong, Whittaker, JC, M R Nelson, Manas, E.S., Yuan, X., D M Waterworth, Whittaker, J.C., Kong, X, Cardon, L, Waterworth, DM, Yuan, X, L Cardon, Mooser, V.E., X Yuan, Song, K., Aponte, J, Bacanu, S-A, Nelson, M.R., Mooser, VE, J C Whittaker, Waterworth, D.M., V E Mooser   +32 more
core   +1 more source

A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022

Frontiers in Endocrinology, 2023
BackgroundSince the approval of the proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for marketing in 2015, PCSK9 inhibitors have attracted significant interest in the field of cardiovascular endocrinology.
Qin Luo, Qin Luo, Zhenchu Tang, Zhenchu Tang, Panyun Wu, Panyun Wu, Zhangling Chen, Zhangling Chen, Zhenfei Fang, Zhenfei Fang, Fei Luo, Fei Luo   +11 more
doaj   +1 more source

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

Lipids in Health and Disease, 2008
Background Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density lipoprotein cholesterol (LDLC) by negatively regulating ...
Mbikay Majambu, LaHaye Stephen A, Lahey Karen A, Chaplin Anna, Cousins Marion, Raymond Angela, Dewpura Thilina, Mayne Janice, Ooi Teik, Chrétien Michel   +9 more
doaj   +1 more source

Small molecules as inhibitors of PCSK9: current status and future challenges [PDF]

, 2019
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating lipoprotein metabolism by binding to low-density lipoprotein receptors (LDLRs), leading to their degradation.
Zhu, Zheying, Shanshan Luo, Jinyi Xu, Luo, Shanshan, Shengtao Xu, Zheying Zhu, Xu, Shengtao, Xu, Jinyi   +7 more
core   +1 more source

Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.

PLoS ONE, 2022
Background and aimsThe LDL cholesterol (LDL-C) treatment goals recommended by the 2019 ESC/EAS guidelines are only achieved in a minority of patients. The study objective was to estimate the impact of bempedoic acid treatment on LDL-C target attainment ...
Julius L Katzmann, Christian Becker, Aikaterini Bilitou, Ulrich Laufs   +3 more
doaj   +1 more source

Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes

Cardiovascular Diabetology, 2020
The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL receptor (LDLR) on the liver cell surface.
Ying Tang, Sheng-Lan Li, Jia-Hui Hu, Kai-Jun Sun, Lei-Ling Liu, Dan-Yan Xu   +5 more
doaj   +1 more source

PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. [PDF]

, 2022
OBJECTIVE To compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant.
Guyatt, Gordon, Delvaux, Nicolas, Bekkering, Geertruida E Trudy, Rodondi, Nicolas, Yedlapati, Siva H., Lone, Ahmad N, Li, Sheyu, Hao, Qiukui, Vandvik, Per Olav, Bekkering, Geertruida E. Trudy, Yedlapati, Siva H, Khan, Safi U., Riaz, Irbaz Bin, Khan, Safi U, Aertgeerts, Bert, Bin Riaz, Irbaz, Lone, Ahmad N.   +16 more
core   +2 more sources